Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Total Current Liabilities
All obligations due within one year.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 10.8% from a year ago
Total current liabilities stood at $10.88M at the end of Q1 FY2026, down 10.8% from a year earlier and down 16.9% from the prior quarter. Over 3 fiscal years it compounded at -20.1% a year.
Context
- Total current liabilities amounted to 10.3% of total assets at the end of Q1 FY2026, up 3.9 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -10.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 13.09M USD
- Year-over-year change
- +6.8%
- 4-year CAGR
- -9.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.09M | +6.8% |
| FY2024 | 2024-12-31 | 12.25M | +0.2% |
| FY2023 | 2023-12-31 | 12.23M | -52.3% |
| FY2022 | 2022-12-31 | 25.63M | +32.7% |
| FY2021 | 2021-12-31 | 19.31M | — |
Total Current Liabilities vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -10.8% is the 3rd highest of 9, against a peer median of -29.2%.
- Total current liabilities amounts to 10.3% of total assets for ARTV, versus a peer median of 14.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $70.81M USD | -46.8% | +4.1% | 29.3% | |
| Mar 2026 | $35.24M USD | -28.7% | -13.6% | 13.9% | |
| Mar 2026 | $20.18M USD | +7.7% | -4.7% | 11.3% | |
| Mar 2026 | $15.41M USD | -18.0% | +35.8% | 15.5% | |
| Dec 2025 | $13.61M USD | +60.9% | -4.5% | 24.3% | |
| Mar 2026 | €11.4M EUR | -29.6% | -0.1% | 23.3% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.88M USD | -10.8% | -20.1% | 10.3% |
| Mar 2026 | $7.76M USD | -37.4% | -46.9% | 5.4% | |
| Mar 2026 | $4.25M USD | -41.9% | -34.4% | 4.2% | |
| Peer median (excluding ARTV) | — | -29.2% | -4.6% | 14.7% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 160.92M | 102.53M | 53.5M | 40.24M | 26.7M |
| Short-term Investments | 0 | 0 | 23.47M | 145.19M | 81.31M |
| Net Receivables | 468K | 525K | 1.76M | 146K | 767K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 1.62M | 1.09M | 3.06M | 3.89M |
| Total Current Assets | 162.29M | 104.68M | 79.82M | 188.63M | 112.67M |
| Property, Plant & Equipment (Net) | 4.08M | 27.62M | 24.64M | 20.43M | 17.36M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 245K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.56M | 517K | 650K | 525K | 919K |
| Total Non-current Assets | 7.64M | 28.38M | 25.29M | 20.95M | 18.27M |
| Total Assets | 169.93M | 133.05M | 105.11M | 209.58M | 130.94M |
| Account Payables | 1.44M | 1.1M | 614K | 1.12M | 355K |
| Short-term Debt | 0 | 0 | 0 | 0 | 3.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.3M | 10.89M | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 2.1M |
| Total Current Liabilities | 19.31M | 25.63M | 12.23M | 12.25M | 13.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 7.88M |
| Deferred Tax Liabilities | 216.41M | 216.41M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 21.68M | 15.64M | 0 | 0 | 0 |
| Other Non-current Liabilities | 81K | 115K | 241.59M | 73K | 0 |
| Total Non-current Liabilities | 239.48M | 248.13M | 254.9M | 10.69M | 7.88M |
| Total Liabilities | 258.78M | 273.75M | 267.13M | 22.94M | 20.97M |
| Common Stock | 0 | 0 | 0 | 3K | 3K |
| Retained Earnings | (93.8M) | (152.59M) | (181.31M) | (246.68M) | (330.55M) |
| Accumulated OCI | 0 | 0 | 308K | (129K) | 103K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (88.86M) | (140.7M) | (162.02M) | 186.64M | 109.97M |
| Total Debt | 1.74M | 19.45M | 16.91M | 14.35M | 10.94M |
| Net Debt | (159.18M) | (83.08M) | (36.59M) | (25.88M) | (15.76M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.